Di bawah ada daftar dengan kolom dan profil perusahaan yang subyeknya berkaitan.

Berita Hari Ini Pharmaceutical Industry

  • Perusahaan Farmasi Merck Indonesia Merencanakan Stock Split di 2015

    Pharmaceutical Company Merck Indonesia Plans Stock Split in 2015

    Perusahaan farmasi Indonesia Merck, yang dikontrol oleh perusahaan jasa kesehatan konsumen dari Jerman Merck Holding GmbH, merencanakan untuk melaksanakan stock split pada tahun 2015 dalam usaha meningkatkan likuiditas dan perdagangan saham perusahaannya. Merck pada saat ini mendiskusikan rencana tersebut dengan Bursa Efek Indonesia dan Otoritas Jasa Keuangan (OJK). Bambang Nurcahyo, Direktur Keuangan Merck, mengatakan bahwa rasio ideal untuk rencana stock split ini adalah 1:20. Sebuah rapat umum pemegang saham akan diadakan pada pertengahan 2015.

    Lanjut baca ›

  • Shares of Indonesia’s Kalbe Farma Hurt by Fatal Medicine Scandal

    Shares of Indonesia’s Kalbe Farma Hurt by Fatal Medicine Scandal

    Shares of Kalbe Farma, Indonesia’s largest pharmaceutical company, have been under pressure over the past couple of days due to the deaths of two hospital patients after they had taken a medicine manufactured by Kalbe Farma. According to the Indonesian Pharmacy Association (GP Farmasi Indonesia) Buvanest Spinal, an anesthetic, was wrongly packaged and hence did not contain bupivacaine but instead tranexamic acid, which aims to stop or reduce heavy bleeding (usually used during surgery).

    Lanjut baca ›

  • Kalbe Farma: a Profile of Indonesia's Largest Pharmaceutical Company

    Indonesia Investments has updated the company profile of PT Kalbe Farma Tbk. Kalbe Farma is the largest listed pharmaceutical company in Indonesia and Southeast Asia (listed on the Indonesia Stock Exchange/IDX). The company’s main business focus rests on four divisions: prescription pharmaceuticals, consumer health products, nutritionals as well as distribution & logistics. Its a leading provider of “comprehensive healthcare solutions”, from pharmaceuticals, nutrition, health foods and beverages to medical devices, including primary healthcare service.

    Lanjut baca ›

  • Phapros to Conduct Initial Public Offering on Indonesia Stock Exchange

    Phapros, subsidiary of state-owned Rajawali Nusantara Indonesia, intends to conduct an initial public offering (IPO) on the Indonesia Stock Exchange in 2015 by offering 10 to 20 percent of its enlarged capital to the public. Through this corporate action, Phapros, a pharmaceutical products manufacturer, aims to raise IDR 500 billion (USD $42.3 million) which will be used to finance the company's capital expenditure in the next two years. The company expects to grow on the implementation of Indonesia’s social security program per 1 January 2014.

    Lanjut baca ›

  • Kimia Farma will Construct Indonesia's First Pharmaceutical Salt Factory

    Indonesian state-controlled pharmaceutical company Kimia Farma will construct Indonesia's first pharmaceutical salt factory in Jombang (East Java) in an attempt to supply the domestic market and curb imports of this type of salt. Minister of State-Owned Enterprises Dahlan Iskan said that the plant can commence operations near the end of 2014 and will have an annual production capacity of 2,000 tons of pharmaceutical salt (approximately two thirds of domestic demand).

    Lanjut baca ›

  • Indonesia´s Largest Herbal Medicine Producer SidoMuncul Plans IPO

    SidoMuncul Herbal, Indonesia´s largest herbal medicine producer, is expected to conduct an initial public offering (IPO) on the Indonesia Stock Exchange (IDX) in the fourth quarter of 2013. The company, established in 1951, is a fully-modernized herbal company that strives to produce and market products that support the people´s health and well-being. The company will release 20 percent of its shares on the IDX and targets to raise IDR 1.5 trillion (USD $130 million). Kresna Securities acts as underwriter for the IPO.

    Lanjut baca ›

Artikel Terbaru Pharmaceutical Industry

  • How Big Indonesian Pharmaceutical Firms Cope with Rupiah Weakness

    How the Big Indonesian Pharmaceutical Firms Cope with Rupiah Weakness

    One of the national industries that is heavily affected by the weak rupiah exchange rate is Indonesia's pharmaceutical industry. Considering around 90 percent of raw materials in the pharmaceutical industry need to be imported from abroad (in US dollars), production costs rise sharply in times of significant rupiah depreciation. It is estimated that materials imported from abroad account for about 75 percent of pharmaceutical companies' total production costs.

    Lanjut baca ›

  • Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Vincent Harijanto, Head of the Indonesian Pharmaceutical Association (GP Farmasi) business development committee, said about 95 percent of raw materials used in Indonesia's pharmaceutical industry need to be imported from abroad. This dependence on imports causes several problems, for example prices of pharmaceutical products are relatively high on the Indonesian market, while Indonesian pharmaceutical companies (and Indonesian consumers) can suddenly face rising prices in times of rupiah depreciation.

    Lanjut baca ›

  • Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Exports of pharmaceutical products from Indonesia have declined due to increasing competition from China on the international market. Chinese pharmaceutical companies dominate export markets supported by China's low production cost environment and the availability of raw materials at home. However, despite this situation, the Indonesian Pharmacy Association (GP Farmasi Indonesia) remains optimistic that Indonesia's pharmaceutical exports can climb in 2017.

    Lanjut baca ›

  • Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    State-controlled pharmaceutical company Kimia Farma is expected to show steadily improving corporate earnings in the years ahead supported by Indonesia's universal healthcare scheme (in Indonesian: Jaminan Kesehatan Nasional or JKN) that was implemented by the social security agency Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS) in early 2014. The scheme aims to provide all Indonesian citizens with access to a wide range of health services. Obviously, local pharmaceutical companies are in a great position to benefit from this program.

    Lanjut baca ›

  • Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Companies active in the pharmaceutical industry of Indonesia need to find strategies to overcome sharp rupiah depreciation. Indonesia’s pharmaceutical industry is still - to a large extent - dependent on the import of raw materials, hence a weakening rupiah raises the costs of imports thus eroding profit margins. Since May 2013, when the US Federal Reserve started to hint at monetary tightening, the US dollar has experienced bullish momentum. Between the May 2013 and July 2015, the rupiah depreciated around 37 percent against the US dollar.

    Lanjut baca ›

Bisnis Terkait Pharmaceutical Industry